How to keep up with dementia research

I read a lot of dementia and Alzheimer's research, because we make a free monthly roundup on it. It's one of the hardest fields to keep up with, because the useful news comes from so many different kinds of source. This is what I've learned about doing it without it taking over your month.

The short answer: pick a small number of sources you trust, check them at a regular time, and write down why something mattered when you save it. Most of this guide is about why that's harder in dementia research than it sounds, and the ways people usually go about it.

Why is dementia research hard to keep up with?

Mostly because it isn't one field. A clinical trial readout, a regulatory decision, a blood biomarker study, a paper on disease biology, a prevention review and a funding announcement can all matter to the same researcher. Each arrives through a different route, with different kinds of detail to check.

Look at September. The FDA cleared C2N's PrecivityAD2 for symptomatic adults aged 40 and older. Acadia's remlifanserin programme moved towards Phase 3 after narrowly missing its primary endpoint. A meta-analysis found modest cognitive benefits from lecanemab alongside a much higher risk of ARIA-E. WHO published a new dementia risk-reduction guideline, and ADNI4 received a five-year $147 million grant.

Some stories need careful reading after the headline. PrecivityAD2 is intended to sit alongside history, examination and cognitive testing, with imaging or CSF where needed. In one study, clinicians' diagnostic accuracy rose from 65% to 93% after seeing the result, but that doesn't make the test a stand-alone diagnosis. And the p-tau217 finding in cognitively unimpaired adults was about estimating risk, not diagnosing dementia.

How do people usually keep up?

Most people use some mix of these:

• Newsletters. Good for a regular overview, because somebody else has done the selecting. The catch is that their selection may favour trials or biomarkers when your work is in care research, prevention or genetics.
• Journal alerts and preprint feeds. The closest you get to new research. They're also noisy, and it takes time to tune alerts so that every new paper doesn't feel urgent.
• Podcasts. Easy to fit into a commute, and useful for hearing why a result matters. Less useful when you need the sample size, endpoint or limitation in front of you.
• Conferences and meetings. Often the first place you'll hear about trial readouts, new biomarker work or studies that haven't appeared in print. They happen only occasionally, and presentations can be hard to revisit later.
• Colleagues and communities. Often how the most relevant papers reach you. It works until the person who normally sends them is busy, or the discussion moves faster than you can follow.

None of them covers everything, so most people end up with a patchwork.

What tends to work

• Keep the list short. Three or four sources you trust are better than fifteen you feel guilty about. If one hasn't given you anything useful in a month, drop it.
• Pick a time. Fifteen minutes on the same day each week works better than trying to catch up whenever you can. For a monthly field roundup, a longer session at the same point in the month can work just as well.
• Write one line when you save something. Why it matters to your work, in a sentence. A bare link rarely gets looked at again, especially when the paper is one of many on the same biomarker or treatment.
• Go back to the source for anything you'll act on. A summary tells you what something is about. For the exact endpoint, sample size, confidence interval or caveat, read the original source.

That's most of it. It takes discipline, and dementia research has enough subfields to make even a sensible routine hard to maintain.

One more option

This is why I built Iris. You describe your work in your own words, something like "blood biomarkers for early Alzheimer's diagnosis and trial recruitment", and every month it reads across the field and writes you a briefing on what changed for you, with every source linked so you can check anything yourself. It can cover clinical trials, regulation, diagnosis, disease mechanisms, prevention, care research and funding in one place.

It's one option, and a good routine with a couple of alerts works well too. If you'd like to see what we cover, our free monthly podcast, Keeping up with Dementia Research is about five minutes on the month's biggest stories, with the written report and every source underneath. When you'd like one built around your own work, you can set up your own briefing.

If you work in dementia research and think I've missed something, I'd like to hear about it: joe@irisbriefings.com.